Direct Oral Anticoagulants for Disseminated Intravascular Coagulation: An Alliterative Wordplay or Potentially Valuable Therapeutic Interventions?

Abstract

Disseminated intravascular coagulation (DIC) is a relatively rare but life-threatening condition, the outcome of which depends largely on timely and accurate therapeutic management. Inhibiting the activation of blood coagulation is an effective option for limiting the burden of diffuse intravascular thrombosis for attenuating consumption of clotting factors and platelets and ultimately preventing massive bleeding. Direct oral anticoagulants (DOACs) are a relatively new generation of drugs that specifically inhibit activated factors II (thrombin) and X, thus providing effective anticoagulation while concomitantly limiting the hemorrhagic risk compared with other conventional anticoagulant agents. The peculiar mechanism of action would hence at least theoretically support their usage in patients with DIC, especially in those with a more pronounced thrombotic phenotype. A comprehensive literature search on the use of DOACs in patients with intravascular coagulopathies currently yielded only 15 documents, all case reports, totaling 21 patients (dabigatran, n = 5; rivaroxaban, n = 13; apixaban, n = 3; edoxaban, n = 0). Taken together, the current literature data suggest that these drugs may have low prophylaxis efficacy and thereby their indication for preventing DIC in high-risk patients may be limited. Nevertheless, DOACs seem at least therapeutically equivalent to heparin in some forms of DIC, especially in those with prevalent thrombotic phenotype, while having more favorable oral administration. The inherent risk of hemorrhages from heparin injection is also shared by DOACs; therefore, their use in DIC patients with a prevalent bleeding phenotype will probably remain unwarranted. Major caution should also be used in patients with impaired drug metabolism, especially those progressing toward liver or renal failure or receiving aggressive antimicrobial treatment. Where potentially indicated, further clinical trials should be planned to test the therapeutic efficacy of these drugs in patients with different types or forms of DIC.

Keywords

direct oral anticoagulants - disseminated intravascular coagulation - thrombosis - treatment

^* These Authors share equal senior authorship on this article.

• References

• 1 Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M. ; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 (05) 1327-1330
• 2 Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J 2006; 4: 4
• 3 Thachil J. The elusive diagnosis of disseminated intravascular coagulation: does a diagnosis of DIC exist anymore?. Semin Thromb Hemost 2019; 45 (01) 100-107
• 4 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341 (08) 586-592
• 5 Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care 2014; 2 (01) 20
• 6 Langer F, Spath B, Haubold K. , et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol 2008; 87 (06) 451-457
• 7 Saba HI, Morelli GA. The pathogenesis and management of disseminated intravascular coagulation. Clin Adv Hematol Oncol 2006; 4 (12) 919-926
• 8 Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care 2014; 2 (01) 15
• 9 Wada H, Thachil J, Di Nisio M. , et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; 11: 761-767
• 10 Levi M, Toh CH, Thachil J, Watson HG. ; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009; 145 (01) 24-33
• 11 Wada H, Asakura H, Okamoto K. , et al; Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010; 125 (01) 6-11
• 12 Di Nisio M, Baudo F, Cosmi B. , et al; Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2012; 129 (05) e177-e184
• 13 Lippi G, Gosselin R, Favaloro EJ. Current and emerging direct oral anticoagulants: state-of-the-art. Semin Thromb Hemost 2019; 45 (05) 490-501
• 14 Lippi G, Mattiuzzi C, Cervellin G, Favaloro EJ. Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. Ann Transl Med 2017; 5 (16) 322
• 15 Lippi G, Favaloro EJ, Simundic AM. Biomedical research platforms and their influence on article submissions and journal rankings: an update. Biochem Med (Zagreb) 2012; 22 (01) 7-14
• 16 ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ . Accessed September 11, 2019
• 17 Simon A, Domanovits H, Ay C, Sengoelge G, Levy JH, Spiel AO. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. J Thromb Haemost 2017; 15 (07) 1317-1321
• 18 Yasumoto A, Ishiura R, Narushima M, Yatomi Y. Successful treatment with dabigatran for consumptive coagulopathy associated with extensive vascular malformations. Blood Coagul Fibrinolysis 2017; 28 (08) 670-674
• 19 Binet Q, Lambert C, Hermans C. Dabigatran etexilate in the treatment of localized intravascular coagulopathy associated with venous malformations. Thromb Res 2018; 168: 114-120
• 20 Randrianarisoa E, Kopp HG, Balletshofer BM. , et al. Management of disseminated intravascular coagulopathy with direct factor Xa inhibitor rivaroxaban in Klippel-Trénaunay syndrome. Blood Coagul Fibrinolysis 2013; 24 (07) 766-770
• 21 Vandenbriele C, Vanassche T, Peetermans M, Verhamme P, Peerlinck K. Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation. J Thromb Thrombolysis 2014; 38 (01) 121-123
• 22 Hayashi T, Nakagawa N, Kadohira Y, Morishita E, Asakura H. Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm: a case report. Ann Intern Med 2014; 161 (02) 158-159
• 23 Kawano H, Hata T, Uda A, Maemura K. Use of rivaroxaban for the effective management of disseminated intravascular coagulation associated with abdominal aortic aneurysm. Intern Med 2015; 54 (20) 2625-2628
• 24 Kadohira Y, Yamada S, Matsuura E. , et al. Aortic aneurysm-associated disseminated intravascular coagulation that responded well to a switch from warfarin to rivaroxaban. Intern Med 2017; 56 (21) 2913-2917
• 25 Poudel DR, Ghimire S, Dhital R, Forman DA, Warkentin TE. Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. Platelets 2017; 28 (06) 614-620
• 26 Huang S, Sun MT, Davis G, Fitzgerald J, Selva D, Henderson T. Bilateral orbital compartment syndrome in a patient with disseminated intravascular coagulation. Orbit 2018; 37 (05) 361-363
• 27 Shimizu Y, Komura T, Seike T. , et al. A case of an elderly female with diffuse hepatic hemangiomatosis complicated with multiple organic dysfunction and Kasabach-Merritt syndrome. Clin J Gastroenterol 2018; 11 (05) 411-416
• 28 Mack JM, Richter GT, Crary SE. Effectiveness and safety of treatment with direct oral anticoagulant rivaroxaban in patients with slow-flow vascular malformations: a case series. Lymphat Res Biol 2018; 16 (03) 278-281
• 29 Manji F. Warkentin TE, Sheppard JI, Lee A. Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban. Platelets 2019; (e-pub ahead of print ). DOI: 10.1080/09537104.2019.1652263.
• 30 De Giglio A, Porreca R, Brambilla M. , et al. Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: does oncogene addiction matter?. Thromb Res 2018; 163: 51-53
• 31 Janjetovic S, Holstein K, Dicke C, Bokemeyer C, Langer F. Apixaban for the treatment of chronic disseminated intravascular coagulation: a report of two cases. Hamostaseologie 2019; 39 (03) 294-297
• 32 Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood 2018; 131 (08) 845-854
• 33 Ding R, Zhao D, Guo R, Zhang Z, Ma X. Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice. Thromb Res 2011; 128 (06) e160-e165
• 34 Lippi G, Favaloro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring?. Semin Thromb Hemost 2014; 40 (07) 756-765
• 35 Tripodi A, Ageno W, Ciaccio M. , et al. Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus 2018; 16 (05) 462-470
• 36 Dompmartin A, Vikkula M, Boon LM. Venous malformation: update on aetiopathogenesis, diagnosis and management. Phlebology 2010; 25 (05) 224-235
• 37 Favaloro EJ, Pasalic L, Curnow J, Lippi G. Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges. Curr Drug Metab 2017; 18 (07) 598-608
• 38 Cervellin G, Benatti M, Bonfanti L, Lippi G. Quality and safety issues of direct oral anticoagulants in the emergency department. Semin Thromb Hemost 2015; 41 (03) 348-354
• 39 Schulman S. Bleeding complications and management on anticoagulant therapy. Semin Thromb Hemost 2017; 43 (08) 886-892
• 40 Lippi G, Sanchis-Gomar F, Favaloro EJ. Andexanet: effectively reversing anticoagulation. Trends Pharmacol Sci 2016; 37 (06) 413-414
• 41 Treceño-Lobato C, Jiménez-Serranía MI, Martínez-García R, Corzo-Delibes F, Martín Arias LH. New anticoagulant agents: incidence of adverse drug reactions and new signals thereof. Semin Thromb Hemost 2019; 45 (02) 196-204